Pfizer-BioNTech’s two-dose Covid-19 vaccine has become the first to receive full approval from the FDA.
The vaccine had initially been given emergency use authorization. Its two shots, three weeks apart, are now fully approved for those aged 16 and older.
The approval is expected to set off more vaccine mandates by employers and organizations across the US.
It comes amid lingering vaccine hesitancy among many Americans.
In a statement, the FDA said its review for approval included data from approximately 44,000 people. The vaccine, which will now be marketed as Comirnaty, was found to be 91% effective in preventing Covid disease.
Acting FDA commissioner Janet Woodcock said that the public “can be very confident” the vaccine meets high safety, effectiveness and manufacturing quality standards.
Pfizer vaccine still has emergency use authorization for children aged 12 to 15.
The vaccine is being provided at no cost to Americans.
The FDA initially gave Pfizer temporary authorization – a clearance given if the agency determines the benefits of a product outweigh potential risks during a public health emergency.
This full approval is essentially permanent. The licensing process requires companies to provide the FDA with information on how and where the product is made, as well as other clinical testing data.
Critics had been calling on the FDA to speed up this approval process as the US struggled with dropping vaccination rates earlier this year. The spread of the contagious Delta variant has already given some hard-hit regions a bump in vaccination rates in recent weeks.
While the agency took steps to increase staff and resources, it had previously said it would take six months to get the required data.
The approval ultimately came less than four months after Pfizer-BioNTech filed for licensing in early May – the fastest vaccine approval in the FDA’s more than 100 year history.
Polling data released at the end of June by the Kaiser Family Foundation found that about 30% of unvaccinated American results said they would be more likely to get a vaccine if it received full FDA approval. The number rises to nearly 50% among Americans taking a “wait and see” approach to vaccines.
In a TV address on August 23, President Joe Biden spoke directly to the “millions” of Americans he said were waiting for full and final FDA approval.
“The moment you’ve been waiting for is here,” he said.
“It’s time for you to go get your vaccination. Get it today.”
Additionally, President Biden called on private sector companies and nonprofits to require employees to get vaccinated or “face strict requirements”.
Companies, healthcare systems, universities and other organizations are now expected to announce vaccine requirements as the country embarks on a return to normalcy. The US military has also said the vaccine will become mandatory for 1.3 million active-duty troops upon FDA approval.
To date, more than 92 million vaccinated Americans – more than half of the total – have received the Pfizer vaccine.
According a study by the University of Texas, the Pfizer/BioNTech vaccine can still target a key mutation that has emerged in two new variants of coronavirus.
However, this is only one of many mutations that are found in the new forms of the virus.
So while the study has been welcomed, it is not being seen as definitive scientific evidence about how the vaccine will perform.
New variants have been detected in the UK and South Africa.
Both variants are spreading more quickly and this has raised questions over what level of protection vaccines can offer against them.
The widely held view is that vaccines will still work, but researchers are on the hunt for proof.
The study focuses on a mutation called N501Y, which is emerged in both new variants.
This is thought to be important because it is in the part of the virus that makes first contact with our body’s cells and changes could make it easier to get in and cause an infection.
The researchers created two forms of the virus – one with and one without the mutation – and then bathed those viruses in blood samples taken from 20 patients that had been vaccinated in clinical trials.
The study results showed the immune systems of vaccinated patients were able to take out the new mutation.
However, the variant that emerged contain multiple mutations whose combined effects may help the virus evade the immune system.
The EU is launching a co-ordinated mass vaccination to fight Covid-19, in what the bloc’s top official Ursula von der Leyen says is a “touching moment of unity”.
On December 26, European Commission President Ursula von der Leyen said the Pfizer-BioNTech vaccine had been delivered to all 27 member states.
Some countries started administering the jabs on the same day, saying they were not prepared to wait another day.
The EU has so far reported more than 335,000 coronavirus-related deaths.
More than 14 million people have been infected, and strict lockdown measures are currently in place in nearly all the member states.
The EU mass vaccination comes as cases of the more contagious variant of the virus are confirmed in several European countries as well as Japan and Canada.
Mass vaccination for the EU’s 446 million people is due to begin in the coming hours.
This comes after the European Medicines Agency (EMA) and the European Commission authorized the German-US Pfizer-BioNTech vaccine.
The EU has secured contracts for more than two billion vaccine doses from a range of drug companies.
Ursula von der Leyen tweeted: “Today, we start turning the page on a difficult year. The #COVID19 vaccine has been delivered to all EU countries. Vaccination will begin tomorrow across the EU. The #EUvaccinationdays are a touching moment of unity. Vaccination is the lasting way out of the pandemic.”
German Health Minister Jens Spahn said on December 26: “This really is a happy Christmas message. At this moment, trucks with the first vaccines are on the road all over Europe, all over Germany, in all federal states. Further deliveries will follow the day after tomorrow.
“This vaccine is the crucial key for defeating the pandemic. It’s the key for us getting back our lives.”
Health workers in north-east Germany decided not to wait for December 27 and started immunizing elderly residents of a nursing home in Halberstadt.
The authorities in Slovakia also said they had begun vaccinating.
Italian Foreign Minister Luigi Di Maio urged his compatriots to get the vaccine: “We’ll get our freedom back, we’ll be able to embrace again.”
In Hungary, the first recipient of the vaccine was a doctor at Del-Pest Central Hospital on December 26, the state news agency says.
Elderly people in care homes and care home staff are top of the priority list, followed by over-80s and health and care staff.
However, because of the limited stocks and need to store at -70C, the very first vaccinations are likely to take place at hospitals so care home residents may not be immunized until later.
The Pfizer/BioNTech product is the fastest vaccine to go from concept to reality, taking only 10 months to follow the same steps that normally span 10 years.
The UK has already ordered 40 million doses of the free jab – enough to vaccinate 20 million people.
The doses will be rolled out as quickly as they can be made by Pfizer in Belgium, Matt Hancock said, with the first load next week and then “several millions” throughout December.
UK’s PM Boris Johnson said: “It’s the protection of vaccines that will ultimately allow us to reclaim our lives and get the economy moving again.”
Pfizer/BioNTech vaccine will be non-compulsory and there will be three ways of vaccinating people across the UK:
Hospitals
Vaccination centers
In the community, with GPs and pharmacists.
Around 50 hospitals are on stand-by and vaccination centers – in venues such as conference centers or sports stadiums – are being set up now.
Because the initial doses are being delivered to hospitals, which already have the facilities to store the vaccine at -70C, the very first vaccinations are likely to take place at hospital hubs – for care home staff, NHS staff and patients – so none of the vaccine is wasted.
It is thought the vaccination network could start delivering more than one million doses a week once enough doses are available.
Pfizer and BioNTech are filing for emergency authorization in the US of their Covid-19 vaccine on Friday, November 20.
The FDA will decide if the vaccine is safe to roll out.
It is not clear how long the FDA will take to study the data. However, the US government expects to approve the vaccine in the first half of December.
Data from an advanced trial showed the vaccine protects 94% of adults over 65.
Pfizer’s and BioNTech’s trial involved 41,000 people worldwide. Half were given the vaccine, and half a placebo.
If FDA authorization does come in the first half of next month, Pfizer and BioNTech will “be ready to distribute the vaccine candidate within hours”, the two companies said.
This would be remarkably quick for vaccine development – within 10 months of detailing the genetic code. The average wait for approval in the US is nearer eight years.
On November 19, Pfizer CEO Albert Bourla said that the filing for emergency use was a “milestone in our journey to deliver a Covid-19 vaccine to the world”.
Initial doses would be scarce, though, and the Centers for Disease Control and Prevention (CDCP) will decide who is first in line.
European Commission president Ursula von der Leyen said the EU could move quickly too – by the end of the year.
Data released this week suggested the Pfizer and BioNTech vaccine had 95% effectiveness.
This effectiveness was also consistent across age groups – essential given the vulnerability of the elderly – as well as ethnicities and gender.
The vaccine also had only mild-to-moderate and short-lived side-effects.
It uses an experimental approach, called mRNA, which involves injecting part of the virus’s genetic code into the body to train the immune system.
Antibodies and T-cells are then made by the body to fight the coronavirus.
The US this week passed 250,000 deaths in the coronavirus outbreak, by far the largest number in the world.
Its confirmed cases since the pandemic began stand at 11.7 million, according to Johns Hopkins University research, again a global first.
Cases have also been soaring over the past week, reaching record daily highs.
This website has updated its privacy policy in compliance with EU GDPR 2016/679. Please read this to review the updates about which personal data we collect on our site. By continuing to use this site, you are agreeing to our updated policy. AcceptRejectRead More
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
_D_(cropped).jpg)
